We intend to focus on healthcare. (Incorporated in the Cayman Islands)

While we may acquire a business in any region globally, we will focus on finding an asset with a strong China nexus. We believe the healthcare sector in Asia has historically benefited from the in-licensing of novel or differentiated therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. Today, we are witnessing the rise of healthcare out-licensing from China, a phenomenon that creates a ‘two-way’ traffic that brings significant benefits to patients in both China and Western countries.

We will focus our search for business combination targets in three verticals of the healthcare industry, namely: pharmaceuticals, medtech and diagnostics.

Bo Tan, our CEO and co-chief investment officer, has over 20 years of extensive experience in the financial and pharmaceutical industries. He was the president and CFO of 3S Bio from December 2016 to December 2019. During his tenure at 3S Bio, Mr. Tan led the privatization of 3SBio and its re-listing in Hong Kong in 2015, as well as the acquisition and integration of Sciprogen, Sirton (Italy), Wanma and CP Guojian.